David Sidransky Net Worth

The estimated Net Worth of David Sidransky is at least $1.34 Million dollars as of 12 October 2022. David Sidransky owns over 8,333 units of Orgenesis Inc stock worth over $476,234 and over the last 17 years he sold ORGS stock worth over $684,696. In addition, he makes $181,118 as Independent Director at Orgenesis Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

David Sidransky ORGS stock SEC Form 4 insiders trading

David has made over 7 trades of the Orgenesis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 8,333 units of ORGS stock worth $26,749 on 12 October 2022.

The largest trade he's ever made was selling 22,808 units of Orgenesis Inc stock on 8 August 2016 worth over $342,348. On average, David trades about 1,907 units every 49 days since 2007. As of 12 October 2022 he still owns at least 770,605 units of Orgenesis Inc stock.

You can see the complete history of David Sidransky stock trades at the bottom of the page.

David Sidransky biography

Dr. David Sidransky M.D. serves as Independent Director of the Company. Dr. Sidransky has served as a director since his appointment on July 18, 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine’s Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC (a Johnson & Johnson diagnostic company), among others and is currently on the board of Directors of Galmed and Rosetta Genomics Ltd. and chairs the board of directors of Advaxis and Champions Oncology, Inc. Dr. Sidransky served as Director from 2005 until 2008 of the American Association for Cancer Research (AACR). In 2006 and 2007, he was the chairperson of AACR International Conferences on Molecular Diagnostics in Cancer Therapeutic Development: Maximizing Opportunities for Personalized Treatment.

What is the salary of David Sidransky?

As the Independent Director of Orgenesis Inc, the total compensation of David Sidransky at Orgenesis Inc is $181,118. There are 7 executives at Orgenesis Inc getting paid more, with Vered Caplan having the highest compensation of $1,577,660.

How old is David Sidransky?

David Sidransky is 60, he's been the Independent Director of Orgenesis Inc since 2013. There are 2 older and 10 younger executives at Orgenesis Inc. The oldest executive at Orgenesis Inc is Prof. Sarah Ferber Ph.D., 67, who is the Founder & Chief Scientific Officer.

Insiders trading at Orgenesis Inc

Over the last 12 years, insiders at Orgenesis Inc have traded over $4,872,134 worth of Orgenesis Inc stock and bought 375,420 units worth $216,187 . The most active insiders traders include Sca Theodorus, Ii Sa Theodorus, and Olivier Belenger. On average, Orgenesis Inc executives and independent directors trade stock every 263 days with the average trade being worth of $1,118,704. The most recent stock trade was executed by Victor Miller on 1 April 2024, trading 25,000 units of ORGS stock currently worth $12,500.

What does Orgenesis Inc do?

orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.

Complete history of David Sidransky stock trades at Ayala Pharmaceuticals, Champions Oncology Inc, Orgenesis Inc, and Ayala Pharmaceuticals

Orgenesis Inc executives and stock owners

Orgenesis Inc executives and other stock owners filed with the SEC include:

• Vered Caplan,
  Chairperson of the Board of Directors, Chief Executive Officer
• Vered Caplan M.Sc.,
  Chairperson of the Board, CEO & Pres
• Darren Head,
  Chief Executive Officer of Masthercell Global
• Neil T. Reithinger CPA,
  CFO, Sec. & Treasurer
• Denis Bedoret,
  President of Masthercell Global
• Sarah Ferber,
  Chief Scientific Officer
• Neil Reithinger,
  Chief Financial Officer, Treasurer, Secretary
• David Sidransky,
  Independent Director
• Guy Yachin,
  Independent Director
• Yaron Adler,
  Independent Director
• Ashish Nanda,
  Independent Director
• Mario Philips,
  Independent Director
• Vincent Vandamme,
  Sr. VP of Quality Strategy
• Lilach Harel,
  VP of Global HR
• Osher Partok Rheinisch,
  Gen. Counsel & Compliance Officer
• Dr. Shimon Hassin Ph.D.,
  Chief Technology Officer
• Joseph Green,
  Chief Operating Officer
• Evan Fishman,
  Chief Financial Officer
• Prof. Sarah Ferber Ph.D.,
  Founder & Chief Scientific Officer
• Elliot Maltz,
  Chief Financial Officer
• Olivier Belenger,
  
• Hugues Bultot,
  Director
• Libre De Bruxelles Universite,
  
• Ii Sa Theodorus,
  
• Sca Theodorus,
  
• Etti Hanochi,
  Director
• Itzhak Vider,
  Director
• Victor Miller,
  CHIEF FINANCIAL OFFICER
• Jacob Safier,
  10% owner
• Mark Goodman,
  Director
• Kunik Efrat Assa,
  Chief Development Officer